Hello, everyone, and how are you this fine morning? A shiny sun is gracing the Pharmalot corporate campus, where the short people are sleeping in due to a break from the schoolhouse. This gives us a welcome opportunity to peacefully peruse the news of the world and brew a delicious cup of stimulation. We would also like to remind you that
we are hosting a webinar next week on Biosimilars and the FDA ( see here) and hope you will join us. Meanwhile, there is still much to be done. So here are some tidbits. Have a great day...Novartis Profit Hurt By Generic Diovan And Consumer Unit Woes (Bloomberg News)
Merck KGgA To Close Swiss Serono Site And Axe 580 Jobs (Bloomberg News)
Watson To Buy Actavis For $6 Billion (Financial Times)
Novartis Challenges UK Avastin Use For Eye Disease (Reuters)
The New Amgen CEO And The Challenges That He Faces (Reuters)
Amgen Founding CEO George Rathmann Dies (Xconomy)
FDA Sent 40 Percent More GMP Letters To Overseas Sites In 2011 (InPharma Technologist)
Nebraska Refuses To Surrender Drug Used For Executions (Regulatory Focus)
Unipharma To Add 44 Jobs In Update New York (Waterbury Republican-American)
EDITOR'S NOTE: Please check this post for updates throughout the day
sunrise pic thx to benimoto on flickr